Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?

نویسندگان

  • Salvatore Brugaletta
  • Jung Ho Heo
  • Hector M Garcia-Garcia
  • Vasim Farooq
  • Robert Jan van Geuns
  • Bernard de Bruyne
  • Dariusz Dudek
  • Pieter C Smits
  • Jacques Koolen
  • Dougal McClean
  • Cecile Dorange
  • Susan Veldhof
  • Richard Rapoza
  • Yoshinobu Onuma
  • Nico Bruining
  • John A Ormiston
  • Patrick W Serruys
چکیده

AIMS To analyse the vasoreactivity of a coronary segment, previously scaffolded by the ABSORB bioresorbable vascular scaffold (BVS) device, in relationship to its intravascular ultrasound-virtual histology (IVUS-VH) composition and reduction in greyscale echogenicity of the struts. Coronary segments, transiently scaffolded by a polymeric device, may in the long-term recover a normal vasomotor tone. Recovery of a normal endothelial-dependent vasomotion may be enabled by scaffold bioresorption, composition of the underlying tissue, or a combination of both mechanisms. METHODS AND RESULTS All patients from the ABSORB Cohort A and B trials, who underwent a vasomotion test and IVUS-VH investigation at 12 and 24 months, were included. Acetylcholine (Ach) and nitroglycerin were used to test either the endothelial-dependent or -independent vasomotion of the treated segment. Changes in polymeric strut echogenicity-a surrogate for bioresorption-IVUS-VH composition of the tissue underneath the scaffold and their relationship with the pharmacologically induced vasomotion were all evaluated. Overall, 26 patients underwent the vasomotion test (18 at 12 and 8 at 24 months). Vasodilatory response to Ach was quantitatively associated with larger reductions over time in polymeric strut echogenicity (y= -0.159x- 6.85; r= -0.781, P< 0.001). Scaffolded segments with vasoconstriction to Ach had larger vessel areas (14.37 ± 2.50 vs. 11.85 ± 2.54 mm(2), P= 0.030), larger plaque burden (57.31 ± 5.96 vs. 49.09 ± 9.10%, P= 0.018), and larger necrotic core (NC) areas [1.39 (+1.14, +1.74) vs. 0.78 mm(2) (+0.20, +0.98), P= 0.006] compared with those with vasodilation. CONCLUSION Vasodilatory response to Ach, in coronary segments scaffolded by the ABSORB BVS device, is associated with a reduction in echogenicity of the scaffold over time, and a low amount of NC. In particular, the latter finding resembles the behaviour of a native coronary artery not caged by an intracoronary device.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.

BACKGROUND Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. METHODS AND RESULTS The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an...

متن کامل

Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.

AIMS Invasive imaging modalities have shown restoration of vasomotion, prevention of restenosis and, most importantly, increase in lumen area between six months and two years after first-generation everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) implantation. Our aim was to assess whether these positive findings were sustained in the long term. METHODS AND RESULTS Patients inc...

متن کامل

Impact of the Everolimus-eluting Bioresorbable Scaffold in Coronary Atherosclerosis.

INTRODUCTION AND OBJECTIVES The Absorb bioresorbable vascular scaffold has been shown to decrease total plaque areas in the treated segment. However, it is unknown whether plaque size is modified in scaffolded segments only or whether the modification extends to other coronary segments. METHODS Absorb Cohort A is a single-arm, prospective study, with safety and imaging endpoints, in which 30 ...

متن کامل

Novel 3-Dimensional Vessel and Scaffold Reconstruction Methodology for the Assessment of Strut-Level Wall Shear Stress After Deployment of Bioresorbable Vascular Scaffolds From the ABSORB III Imaging Substudy.

A 72-year-old female patient underwent successful deployment of a single 3.0 18 mm Absorb bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, California) to the mid right coronary artery (Figures 1A and 1B). The scaffolded segment was imaged simultaneously with coronary angiography and with the C7 Dragonfly (LightLab Imaging Inc., St. Jude Medical, Westford, Massachusetts) optical co...

متن کامل

Bioresorbable vascular scaffolds in daily clinical practice: is the essential really invisible to the eyes?

SEE PAGE 791 B ioresorbable vascular scaffolds (BVS) boast the unique ability to satisfy the temporary need for mechanical support during initial arterial healing following percutaneous coronary revascularization, obviating the long-term disadvantages of permanent metallic prostheses. Based on the results of the ABSORB trial cohort A (n 1⁄4 30) (1) and cohort B (n 1⁄4 101) (2), the Absorb BVS (...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • European heart journal

دوره 33 11  شماره 

صفحات  -

تاریخ انتشار 2012